Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in STEMI patients undergoing primary PCI
NCT03718286Phase 2Completed
- Sponsor
- Population Health Research Institute
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alirocumab in hypercholesterolemia, sponsored by Population Health Research Institute. Started Mar 2019; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03718286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718286.